Mindbloom

Mindbloom is a mental health and wellness company that delivers at-home ketamine therapy for depression and anxiety through a telemedicine-enabled care model. The company combines licensed clinician oversight with guided digital experiences to support patients throughout their treatment journey, from initial consultation to ongoing sessions conducted in the comfort of their own homes. By integrating technology into every stage of care, Mindbloom has created a scalable platform that removes traditional barriers to accessing psychedelic-assisted therapy, including cost, geography, and stigma. Their approach pairs pharmaceutical treatment with structured digital programming designed to maximize therapeutic outcomes and patient engagement.

Headquartered in New York, NY, Mindbloom has raised $25 million in Series A funding, signaling strong investor confidence in its technology-enabled care model. The company has treated tens of thousands of patients, establishing one of the largest real-world datasets for ketamine therapy in a direct-to-consumer context. This scale of deployment positions Mindbloom as a significant clinical operator in the emerging psychedelic medicine space, with growing evidence of its model's safety and effectiveness across a broad patient population. Their ability to deliver measurable outcomes at scale distinguishes them from smaller clinic-based providers still operating in a traditional healthcare framework.

Mindbloom represents an important inflection point for the neurotech and mental health tech industries by demonstrating that psychedelic-assisted therapies can be delivered responsibly outside of clinical settings through well-designed digital infrastructure. As the mental health crisis continues to strain conventional treatment systems, companies like Mindbloom offer a viable path to expanding access to interventions that have shown significant promise for treatment-resistant conditions. Their model also generates longitudinal patient data that could inform future research, regulatory frameworks, and the broader development of psychedelic medicine as a recognized therapeutic category. For investors and industry observers, Mindbloom exemplifies how neurotechnology and digital health can converge to reshape the standard of care in psychiatry.